Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Falzarano, Darryl ^a   De Wit, Emmie ^a   Martellaro, Cynthia ^a   Callison, Julie ^a   Munster, Vincent J ^a   Feldmann, Heinz ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; RIBAVIRIN;

ANIMAL; ARTICLE; CERCOPITHECUS; CORONAVIRUS; DRUG COMBINATION; DRUG EFFECT; PHYSIOLOGY; VERO CELL; VIRUS REPLICATION;

ANIMALS; CERCOPITHECUS AETHIOPS; CORONAVIRUS; DRUG COMBINATIONS; INTERFERON-ALPHA; RIBAVIRIN; VERO CELLS; VIRUS REPLICATION;

EID: 84879840922     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep01686     Document Type: Article

References (49)

1. Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. & Fouchier, R. A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. The New England journal of medicine 367, 1814-1820 (2012).
2. Buchholz, U. et al. Contact investigation of a case of human novel coronavirus infection treated in a German hospital, October-November 2012. Euro surveillance: bulletin europeen sur les maladies transmissibles 5 European communicable disease bulletin 18, pii520406 (2013).
3. World Health Organization. Novel coronavirus infection-update. (2013),http://www.who.int/csr/don/2013-02-21/en/index.html. [Accessed March 4, 2013].
4. Wise, J. Patient dies from novel coronavirus in UK. BMJ 346, f1133 (2013).
5. van Boheemen, S. et al. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. mBio 3, e00473-12, doi:10.1128/mBio.00473-12 (2012).
6. Woo, P. C. et al. Comparative analysis of twelve genomes of three novel group 2c and group 2d coronaviruses reveals unique group and subgroup features. Journal of virology 81, 1574-1585 (2007).
7. Evidence of person-to-person transmission within a family cluster of novel coronavirus infections, United Kingdom, February 2013. Euro surveillance: bulletin europeen sur les maladies transmissibles 5 European communicable disease bulletin 18, pii520427 (2013).
8. Holmes, K. V. & Dominguez, S. R. The new age of virus discovery: genomic analysis of a novel human betacoronavirus isolated from a fatal case of pneumonia. mBio 4, e00548-12, doi:10.1128/mBio.00548-12 (2013).
9. Muller, M. A. et al. Human Coronavirus EMC Does Not Require the SARSCoronavirus Receptor and Maintains Broad Replicative Capability in Mammalian Cell Lines. mBio 3, e00515-12, doi:10.1128/mBio.00515-12 (2012).
10. Li, W. et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426, 450-454 (2003).
11. Raj, V. S. et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495, 251-254 (2013).
12. Peiris, J. S. et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 361, 1767-1772 (2003).
13. Sung, J. J. et al. Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. Thorax 59, 414-420 (2004).
14. Booth, C.M. et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA: the journal of the American Medical Association 289, 2801-2809 (2003).
15. Chan, K. S. et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong medical journal 5 Xianggang yi xue za zhi/Hong Kong Academy of Medicine 9, 399-406 (2003).
16. Chu, C. M. et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 59, 252-256 (2004).
17. Loutfy, M. R. et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA: the journal of the American Medical Association 290, 3222-3228 (2003).
18. Wong, S. S. & Yuen, K. Y. The management of coronavirus infections with particular reference to SARS. The Journal of antimicrobial chemotherapy 62, 437-441 (2008).
19. Shah, N. R., Sunderland, A. & Grdzelishvili, V. Z. Cell type mediated resistance of vesicular stomatitis virus and Sendai virus to ribavirin. PloS one 5, e11265, doi:10.1371/journal.pone.0011265 (2010).
20. Pearlman, B. L. Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care. The Lancet infectious diseases 12, 717-728 (2012).
21. Paeshuyse, J., Dallmeier, K. & Neyts, J. Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action. Current opinion in virology 1, 590-598 (2011).
22. Wise, J. Two more cases of novel coronavirus are confirmed in UK. BMJ 346, f1030 (2013).
23. Haagmans, B. L. et al. Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nature medicine 10, 290-293 (2004).
24. Kumaki, Y. et al. Induction of interferon-gamma-inducible protein 10 by SARSCoV infection, interferon alfacon 1 and interferon inducer in human bronchial epithelial Calu-3 cells and BALB/c mice. Antiviral chemistry & chemotherapy 20, 169-177 (2010).
25. Kumaki, Y. et al. Single-dose intranasal administration with mDEF201 (adenovirus vectored mouse interferon-alpha) confers protection from mortality in a lethal SARS-CoV BALB/c mouse model. Antiviral research 89, 75-82 (2011).
26. Gowen, B. B. et al. Extended protection against phlebovirus infection conferred by recombinant adenovirus expressing consensus interferon (DEF201). Antimicrobial agents and chemotherapy 56, 4168-4174 (2012).
27. Morgenstern, B., Michaelis, M., Baer, P. C., Doerr, H. W. & Cinatl, J. Jr. Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochemical and biophysical research communications 326, 905-908 (2005).
28. Saijo, M. et al. Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus. Antiviral research 66, 159-163 (2005).
29. Kumaki, Y. et al. Interferon alfacon 1 inhibits SARS-CoV infection in human bronchial epithelial Calu-3 cells. Biochemical and biophysical research communications 371, 110-113 (2008).
30. Sainz, B. Jr., Mossel, E. C., Peters, C. J. & Garry, R. F. Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). Virology 329, 11-17 (2004).
31. Zheng, B. et al. Potent inhibition of SARS-associated coronavirus (SCOV) infection and replication by type I interferons (IFN-alpha/beta) but not by type II interferon (IFN-gamma). Journal of interferon & cytokine research: the official journal of the International Society for Interferon and Cytokine Research 24, 388-390 (2004).
32. Paragas, J., Blatt, L. M., Hartmann, C., Huggins, J. W. & Endy, T. P. Interferon alfacon1 is an inhibitor of SARS-corona virus in cell-based models. Antiviral research 66, 99-102 (2005).
33. Hensley, L. E. et al. Interferon-beta 1a and SARS coronavirus replication. Emerging infectious diseases 10, 317-319 (2004).
34. Stroher, U. et al. Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-alpha. The Journal of infectious diseases 189, 1164-1167 (2004).
35. Koren,G., King, S., Knowles, S.&Phillips, E. Ribavirin in the treatment of SARS:A new trick for an old drug? CMAJ: Canadian Medical Association journal5journal de l'Association medicale canadienne 168, 1289-1292 (2003).
36. Cinatl, J. et al. Treatment of SARS with human interferons. Lancet 362, 293-294 (2003).
37. Lee, N. et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. The New England journal of medicine 348, 1986-1994 (2003).
38. Poutanen, S. M. et al. Identification of severe acute respiratory syndrome in Canada. The New England journal of medicine 348, 1995-2005 (2003).
39. Tsang, K. W. et al. A cluster of cases of severe acute respiratory syndrome inHong Kong. The New England journal of medicine 348, 1977-1985 (2003).
40. Tsang, K. & Seto, W. H. Severe acute respiratory syndrome: scientific and anecdotal evidence for drug treatment. Current opinion in investigational drugs 5, 179-185 (2004).
41. Groneberg, D. A. et al. Treatment and vaccines for severe acute respiratory syndrome. The Lancet infectious diseases 5, 147-155 (2005).
42. Brochot, E. et al. Ribavirin monitoring in chronic hepatitis C therapy: anaemia versus efficacy. Antiviral therapy 15, 687-695 (2010).
43. Bausch, D. G., Hadi, C. M., Khan, S. H. & Lertora, J. J. Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 51, 1435-1441 (2010).
44. Chen, F. et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology 31, 69-75 (2004).
45. Weiss, R. C. & Oostrom-Ram, T. Inhibitory effects of ribavirin alone or combined with human alpha interferon on feline infectious peritonitis virus replication in vitro. Veterinary microbiology 20, 255-265 (1989).
46. Wills, R. J. Clinical pharmacokinetics of interferons. Clinical pharmacokinetics 19, 390-399 (1990).
47. Hausfater, P., Cacoub, P., Assogba, U., Lebon, P. & Piette, J. C. Plasma exchange and interferon-alpha pharmacokinetics in patients with hepatitis C virusassociated systemic vasculitis. Nephron 91, 627-630 (2002).
48. Corman, V. M. et al.Detection of a novel human coronavirus by real-time reversetranscription polymerase chain reaction. Euro surveillance: bulletin europeen sur les maladies transmissibles 5 European communicable disease bulletin 17, pii520285 (2012).
49. Reed, L. J. & Muench, H. A. A simple method for estimating fifty percent endpoints. American journal of hygiene 27, 493-497 (1938).